Evogene Stock Set to Reverse Split on Thursday, July 25th (NASDAQ:EVGN)

Evogene Ltd. (NASDAQ:EVGN) shares are going to reverse split on Thursday, July 25th. The 1-10 reverse split was announced on Tuesday, July 23rd. The number of shares owned by shareholders will be adjusted after the market closes on Wednesday, July 24th.

Evogene Stock Performance

Shares of NASDAQ EVGN traded down $0.09 during midday trading on Tuesday, hitting $0.53. 967,561 shares of the stock traded hands, compared to its average volume of 138,161. The firm has a 50-day moving average of $0.67 and a two-hundred day moving average of $0.75. The firm has a market capitalization of $21.85 million, a P/E ratio of -1.15 and a beta of 1.40. Evogene has a one year low of $0.45 and a one year high of $1.12.

Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Thursday, May 23rd. The biotechnology company reported ($0.08) earnings per share for the quarter. The firm had revenue of $4.19 million for the quarter. Evogene had a negative net margin of 233.66% and a negative return on equity of 70.96%.

Wall Street Analysts Forecast Growth

Separately, StockNews.com began coverage on Evogene in a report on Sunday. They issued a “sell” rating on the stock.

Institutional Investors Weigh In On Evogene

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets grew its position in shares of Evogene Ltd. (NASDAQ:EVGN) by 30.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 91,400 shares of the biotechnology company’s stock after purchasing an additional 21,500 shares during the period. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 at the end of the most recent reporting period. 10.40% of the stock is owned by institutional investors and hedge funds.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.